Circulating Tumor DNA as a Prognostic Marker in HR+/HER2- Breast Cancer
A discussion on the use of circulating tumor DNA (ctDNA) as a prognostic biomarker in HR+/HER2- breast cancer.
Evolving Treatment Paradigms Recent Data Updates Prognostic Marker Hr Her2 Breast Cancer Cdk4 6 Inhibitors Penelope B
Source: onclive.com